Corporate Partnerships
Together, We Can Make a Lasting Impact
At the Epilepsy Foundation, our mission is to improve the lives of people affected by epilepsy through education, advocacy, research, and connection. Guided by this mission we work every day to empower journeys, break down barriers, raise awareness, and expand access to care.
Through the support of our corporate partners, we’ve made meaningful progress in improving the lives of the nearly 3.4 million people living with epilepsy in the United States. Our impact is amplified by collaboration, and we welcome companies to stand with us as we pursue our vision of a world where no one faces epilepsy alone.
We invite you to join us in this work. Corporate partnerships are tailored to align with your goals while advancing meaningful change for the epilepsy community.
Lifetime Giving
The Lyte Guild – Lifetime Giving over $5 Million
The Lyte Guild is a distinguished circle of corporate partners whose lifetime giving to the Epilepsy Foundation exceeds $5 million, reflecting their profound and sustained commitment to transforming the lives of people with epilepsy. Named in honor of Henry Lyte, who in 1578 was the first to translate and help shift the perception of epilepsy from a mystical “sacred disease” to a medically understood condition, the Lyte Guild embodies the spirit of progress, science, and hope. Just as Lyte’s work helped ignite a change in how epilepsy was viewed and treated, members of the Lyte Guild are catalysts for change today—fueling research, advocacy, education, and connection that move us closer to a world where no one faces epilepsy alone.
MEMBERS:
Savers, Inc.
Savers, a for-profit thrift retailer with over 300 locations across the U.S., Canada, and Australia, supports nonprofit organizations by purchasing donated goods and reselling them to fund community programs. Through its partnership with the Epilepsy Foundation, Savers helped raise funds by paying the Foundation for every donation of clothing and household items it received. This collaboration supported epilepsy programs in multiple regions, turning donated goods into critical funding for services like art therapy and public education.
UCB Pharma, Inc.
UCB is a global biopharmaceutical company focusing on neurology and immunology. They are committed to developing treatments for epilepsy, including medications like Briviact® (brivaracetam) and Vimpat® (lacosamide), enhancing patient quality of life through seizure control.
The Jackson Circle – Lifetime Giving over $2 Million
The Jackson Circle honors companies whose lifetime giving to the Epilepsy Foundation surpasses $2 million—an extraordinary commitment that fuels innovation and transforms lives. Named for Dr. John Hughlings Jackson, a 19th-century neurologist who pioneered the understanding of epilepsy as a neurological condition rooted in brain activity, this elite circle pays tribute to those who lead with vision and science. Just as Jackson’s discoveries laid the groundwork for today’s treatments, members of the Jackson Circle advance groundbreaking research, education, and connection. Their legacy is one of leadership, partnership, and a future where epilepsy is no longer feared but understood and overcome.
MEMBERS:
Eisai, Inc.
Eisai is a Japanese pharmaceutical company dedicated to human healthcare, focusing on neurology and oncology. They are known for their work in Alzheimer's disease, including the development of lecanemab (Leqembi®), as well as their development of the antiseizure medications, including Fycompa® (perampanel), approved for partial-onset and generalized tonic-clonic seizures.*
Jazz Pharmaceuticals
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families.
We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
We have a diverse portfolio of marketed medicines including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.
Lundbeck
Lundbeck is a global pharmaceutical company focused on brain diseases. They develop treatments for epilepsy, depression, and other CNS disorders, striving to improve patient outcomes.
Sumitomo Pharmaceuticals
Sumitomo Pharma America, Inc. (SMPA), formed in 2023 and based in Cambridge, MA, is a U.S. biopharmaceutical company focused on innovative treatments in psychiatry, neurology, oncology, and rare diseases. Its portfolio includes APTIOM®, an antiepileptic medication, and a broad pipeline of therapies supported by advanced data and technology.
Annual Giving
Trailblazer – Over $500,000 in Annual Giving
As a Trailblazer, your commitment to the Epilepsy Foundation is nothing short of transformative. With a gift of over $500,000 annually, you are helping us break new ground in epilepsy research, advocacy, and support. Just as trailblazers lead the way into uncharted territory, your generosity is paving the way for groundbreaking advances that improve the lives of people living with epilepsy. Your leadership helps ensure every epilepsy journey begins and stays filled with empowerment.
Visionary – Over $250,000 in Annual Giving
Visionaries are the cornerstone of progress in our mission to create a world free of epilepsy. With gifts of over $250,000 annually, you help us envision and build a future where people living with epilepsy have access to cutting-edge treatments, comprehensive care, and unwavering support. Your forward-thinking leadership shapes the next generation of epilepsy research and advocacy, empowering those affected by seizures to live healthier, fuller lives.
FISCAL YEAR 2025 MEMBERS:
Jazz Pharmaceuticals
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families.
We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
We have a diverse portfolio of marketed medicines including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.
Neurelis
Neurelis, Inc. is an innovation-driven neuroscience company focused on the development and commercialization of product candidates and innovative delivery technologies for the broader central nervous system (CNS), including epilepsy and psychiatry. In 2020, Neurelis reached a milestone in patient care with its first FDA-approved treatment. For information, please visit here.
UCB Pharma, Inc.
UCB is a global biopharmaceutical company focusing on neurology and immunology. They are committed to developing treatments for epilepsy, including medications like Briviact® (brivaracetam) and Vimpat® (lacosamide), enhancing patient quality of life through seizure control.
Innovator – Over $100,000 in Annual Giving
As an Innovator, your annual contribution of over $100,000 drives meaningful change and sparks new possibilities. Your generosity fuels groundbreaking research, advances new treatments, expands educational resources, and builds a stronger community where no one faces epilepsy alone. Thanks to your visionary support, we can continue to create a future filled with hope and progress for all those affected by epilepsy.
FISCAL YEAR 2025 MEMBERS:
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a patient-centric biopharmaceutical company committed to improving the lives of those with rare diseases. Their portfolio includes FYCOMPA® (perampanel), an FDA-approved therapy for partial-onset seizures in patients aged four and older, and primary generalized tonic-clonic seizures in patients aged 12 and older.
Livanova
As pioneers of the VNS Therapy™ System, we continue to advance medical device solutions for people affected by treatment-resistant epilepsy. We strive to help where it really counts, where it truly matters the most. Sharp, responsive and effective – at LivaNova we serve health and improve lives. Day by day. Life by life.
SK Life Science
SK Life Science is a pharmaceutical company specializing in CNS disorders. They developed XCOPRI® (cenobamate), approved for the treatment of partial-onset seizures in adults, offering a new option for patients with epilepsy.
Community Leader – Over $50,000 in Annual Giving
Community Leaders are the heart of our mission. With gifts of over $50,000 annually, you help build a strong, supportive network for those affected by epilepsy. Your contribution ensures that we can offer vital programs, raise awareness, and provide essential resources to families and individuals living with seizures. As a Community Leader, you're helping foster a sense of belonging and support that brings people closer and makes a real impact.
FISCAL YEAR 2025 MEMBERS:
Biocodex
Biocodex USA is the American subsidiary of Biocodex, a French family-owned pharmaceutical company established in 1953. With a global presence in over 100 countries, Biocodex focuses on three primary areas: microbiota care, women's health, and orphan diseases. In the U.S., Biocodex is known for products like DIACOMIT® (stiripentol), used in treating Dravet syndrome, a rare and severe form of epilepsy.
Eisai, Inc.
Eisai is a Japanese pharmaceutical company dedicated to human healthcare, focusing on neurology and oncology. They are known for their work in Alzheimer's disease, including the development of lecanemab (Leqembi®), as well as their development of the antiseizure medications, including Fycompa® (perampanel), approved for partial-onset and generalized tonic-clonic seizures.
Pfizer
Pfizer is a global pharmaceutical company with a broad portfolio of medicines and vaccines. Their commitment to neuroscience includes developing treatments for epilepsy and other CNS disorders.
Savers, Inc.
Savers, a for-profit thrift retailer with over 300 locations across the U.S., Canada, and Australia, supports nonprofit organizations by purchasing donated goods and reselling them to fund community programs. Through its partnership with the Epilepsy Foundation, Savers helped raise funds by paying the Foundation for every donation of clothing and household items it received. This collaboration supported epilepsy programs in multiple regions, turning donated goods into critical funding for services like art therapy and public education.
Xenon Pharmaceuticals
Xenon is a neuroscience-focused biopharmaceutical company developing therapies for neurological and psychiatric disorders. Their pipeline includes treatments for epilepsy and depression, addressing areas of high unmet medical need.
The Epilepsy Corporate Alliance (ECA)
The Epilepsy Corporate Alliance brings together industry partners and the Epilepsy Foundation of America to drive meaningful impact for people living with epilepsy. Through exclusive access to Foundation leadership and strategic insights, members stay informed on key priorities, emerging needs, and opportunities for collaboration. By fostering alignment and partnership, the Alliance accelerates innovative solutions that improve health outcomes and strengthen support for the epilepsy community.
Current Members
Eisai
Eisai is a Japanese pharmaceutical company dedicated to human healthcare, focusing on neurology and oncology. They are known for their work in Alzheimer's disease, including the development of lecanemab (Leqembi®), as well as their development of the antiseizure medications, including Fycompa® (perampanel), approved for partial-onset and generalized tonic-clonic seizures.
GeneDx
GeneDx is a global leader in genomic testing and the #1 genetic test, focused on diagnosing rare and complex genetic conditions. By leveraging one of the world’s largest rare disease data sets, GeneDx delivers timely, actionable insights that help end diagnostic odysseys and guide more personalized care.
Jazz Pharmaceuticals
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families.
We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
We have a diverse portfolio of marketed medicines including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.
Livanova
As pioneers of the VNS Therapy™ System, we continue to advance medical device solutions for people affected by treatment-resistant epilepsy. We strive to help where it really counts, where it truly matters the most. Sharp, responsive and effective – at LivaNova we serve health and improve lives. Day by day. Life by life.
Lundbeck
Lundbeck is a global pharmaceutical company focused on brain diseases. They develop treatments for epilepsy, depression, and other CNS disorders, striving to improve patient outcomes.
Neurelis
Neurelis, Inc. is an innovation-driven neuroscience company focused on the development and commercialization of product candidates and innovative delivery technologies for the broader central nervous system (CNS), including epilepsy and psychiatry. In 2020, Neurelis reached a milestone in patient care with its first FDA-approved treatment. For information, please visit here.
uniQure
uniQure is a biotechnology company focused on developing innovative gene therapies for patients with severe genetic and neurological diseases. Headquartered in Amsterdam, the company leverages its proprietary adeno-associated virus (AAV) gene therapy platform to create treatments designed to address the underlying causes of disease, often with the potential for long-lasting or one-time therapies.
Waymo
Waymo is an autonomous driving technology company with a mission to be the world's most trusted driver. Waymo offers a 24/7 ride-hailing service in 10 US cities with a "driver" who is never drunk, distracted, drowsy or emotional. This technology has the potential to save lives, increase independence and improve mobility access for many who cannot or choose not to drive. Waymo is proud to support a diverse set of communities and organizations to build a future where everyone can travel safely and with ease.
Xenon Pharmaceuticals
Xenon is a neuroscience-focused biopharmaceutical company developing therapies for neurological and psychiatric disorders. Their pipeline includes treatments for epilepsy and depression, addressing areas of high unmet medical need.
Hear from our Partners
“The Epilepsy Foundation of America is often the first point of contact for individuals when they receive an epilepsy diagnosis. SK Life Science is proud to partner with the Foundation because we align with their mission to educate, advocate, and discover cures for the various forms of epilepsy. At SK Life Science, we are driven by health and happiness, a vision that resonates with the Epilepsy Foundation's commitment to enhancing patient outcomes and supporting individuals through their journey. By working together, we leverage our combined expertise and resources to navigate challenges, foster community support, and drive meaningful progress in the fight against epilepsy.” -W. Jason Griffith, Associate Director, Marketing, SK Life Science
"We see the direct impact to patients and families from this well-respected organization and look forward to many more years of partnership and collaboration," Lara Falcon, US Advocacy Lead - Epilepsy & Rare Syndromes, UCB
“Partnering with the Epilepsy Foundation allows partners to make a significant impact on the epilepsy community. For over two decades, UCB has proudly supported the Foundation's work, which amplifies patient and caregiver voices in healthcare, legislation, and communities nationwide. The reputation Epilepsy Foundation has earned in their decades of advocacy and service to the epilepsy community has been so impactful and meaningful to UCB and many other organizations, institutions and governments. We see the direct impact to patients and families from this well-respected organization and look forward to many more years of partnership and collaboration.” - Lara Falcon, US Advocacy Lead - Epilepsy & Rare Syndromes, UCB
“Our collaboration with the Epilepsy Foundation offers a unique opportunity to make a meaningful impact aligned with our brand purpose. Our mutual interest in improving the lives of the epilepsy community fosters a synergistic relationship that helps support our business goals. It allows our brand to connect with an engaged audience and demonstrate our commitment to social responsibility.” - Jennifer Lively, Senior Marketing Manager, LivaNova
"This collaboration shows the incredible results we can achieve when patient advocacy groups and industry come together with a shared vision," Amy Grover, Executive Director, Patient Advocacy. Catalyst Pharmaceuticals
“Our partnership with the Epilepsy Foundation has been valuable in offering educational and support opportunities for those affected by epilepsy, as we've raised awareness and delivered impactful programs that empower this community. This collaboration shows the incredible results we can achieve when patient advocacy groups and industry come together with a shared vision.” - Amy Grover, Executive Director, Patient Advocacy. Catalyst Pharmaceuticals
Join Us as a Partner
If you're interested in exploring current opportunities or creating new ways to drive awareness and advance the mission of the Epilepsy Foundation, we’d love to connect. Each partnership is thoughtfully tailored to align with your company’s goals, priorities, and level of investment.
Resources
Epilepsy Centers
Epilepsy centers provide you with a team of specialists to help you diagnose your epilepsy and explore treatment options.
Epilepsy Medication
Find in-depth information on anti-seizure medications so you know what to ask your doctor.
Epilepsy and Seizures Helpline
Call our Epilepsy and Seizures Helpline and talk with an epilepsy information specialist or submit a question online.
Tools & Resources
Get information, tips, and more to help you manage your epilepsy.
Related Stories
Press Releases
Joyce A. Cramer to Receive Lifetime Accelerator Award for Transformative Contributions to Clinical Research and Epilepsy Innovation
Read Story
